Single Center, Single Group Assignment, Open Label Trial to Assess Safety and Effectiveness of Intravenous Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With Recessive Dystrophic Epidermolysis Bullosa
Overview
- Phase
- Phase 1
- Intervention
- Human Umbilical Cord Blood-derived Mesenchymal Stem Cells
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Sponsor
- Gangnam Severance Hospital
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Adverse events related to the intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Previously, many studies have been conducted on mesenchymal stem cells derived from bone marrow or subcutaneous fat, but interest in cord blood-derived mesenchymal stem cell treatments has been increasing recently.
In the case of cord blood as a source, the isolation of mesenchymal stem cells is easier than bone marrow or fat tissue, and cord blood-derived mesenchymal stem cells have an advantage as a treatment because they have faster population doubling time.
To date, no clinical research on the treatment of patients using cord blood-derived mesenchymal stem cells has been reported in the literature, but there have already been registered at clinicaltrials.gov and currently being conducted overseas.
In this study, we will study the safety and effectiveness of RDEB patient treatment using cord blood-derived mesenchymal stem cells with these advantages.
Detailed Description
Until now, all clinical trials for Recessive Dystrophic Epidermolysis Bullosa (RDEB) have examined the potential of bone marrow-derived MSCs. However, umbilical cord blood (UCB) is another important source of stem cells, since its non-invasive collection procedure and rapid availability from cord blood banking. Human UCB-derived MSCs (hUCB-MSCs) exhibit high proliferation capacity and low immunogenicity. A few data support that UCB-MSCs may have significantly greater immunosuppressive potential than other sources of MSCs. A preclinical study has demonstrated that systemic infusions of human UCB-derived unrestricted somatic stem cells, a subpopulation of non-hematopoietic stromal stem cells, significantly extended the life span and reduced blistering of RDEB mice model. Given the promising results of the preclinical study, we conducted a first-in-human, phase 1/2a clinical trial of intravenous administrations of allogeneic hUCB-MSCs in patients with RDEB to determine the safety, tolerability, and potential efficacy.
Investigators
Sang Eun Lee
Assistant professor
Gangnam Severance Hospital
Eligibility Criteria
Inclusion Criteria
- •Patients who diagnosed with recessive dystrophic epidermolysis bullosa through clinical, histological(Partial or complete loss of VII collagen (C7) should be confirmed by DIF and electron microscopy examination) and genetic testing(COL7A1 Genetic mutation must be confirmed).
- •RDEB patients aged 10 to 60 years old (In the case of patients under the age of 19, patients who obtain consent from a representative (parental authority or guardian))
- •Patients who have heard the purpose and contents of a clinical trial and voluntarily signed the consent form prior to the clinical trial (Legal representative in case of minor)
- •Patients who can be monitored during a clinical trial period
Exclusion Criteria
- •Patients who disagree with this study
- •Patients who is not accompanied by a guardian if those with impaired consent ability
- •Patient or the patient's representative is unable to hear and understand the explanation
- •In case of received immunotherapy or chemotherapy including oral corticosteroid (topical treatment is possible) for more than 1 week within 8 weeks before registration.
- •All kinds of live vaccines except influenza vaccine within four weeks prior to registration
- •Clinically significant infections within four weeks of the screening date or during the screening period (pneumonia, pyelonephritis, Clostridium difficile etc)
- •All kinds of confirmed congenital or acquired immunodeficiency syndrome
- •Acute, chronic infection (Type B, Type C) corresponding to:
- •HBs-Ag, IgM anti-HBc, IgG anti-HBc positive (However, if HBs-Ag and IgM anti-HBc is negative, but only IgG anti-HBc is positive, if ani-HBs Ab positive, this clinical trial can be registered.)
- •Patients who with allogenic stem cell treatment experience within 1 year from the screening test date
Arms & Interventions
FURESTEM-CD Inj
Intervention: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells
Outcomes
Primary Outcomes
Adverse events related to the intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell
Time Frame: 8 months
Secondary Outcomes
- Change in pain visual analogue scale (VAS)(baseline, day56, day 112, day168)
- Change in type VII collagen and anchoring fibril expression at dermoepidermal junction(baseline, day 56)
- Change in Global severity score(baseline, day56, day 112, day168)
- Change in Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire(baseline, day56, day 112, day168)
- Change in blister count(baseline, day56, day 112, day168)
- Change in pruritus visual analogue scale (VAS)(baseline, day56, day 112, day168)
- Change in Birmingham Epidermolysis Bullosa Severity Score (BEBSS)(baseline, day56, day 112, day168)
- Change in total body surface area affected by RDEB(baseline, day56, day 112, day168)